紫杉醇联合卡铂化疗治疗卵巢癌的效果分析

Effect of Paclitaxel Combined With Carboplatin on Ovarian Cancer

目的探讨紫杉醇联合卡铂化疗治疗卵巢癌的效果分析。方法选自2018年5月-2019年5月132名符合入组以及排除标准的患者,随后研究人员将患者分为对照组以及研究组,分组应按照科学、合理、随机的标准,两组患者分别均有67例,对照组患者按照研究要求,接受卡铂化疗治疗,研究组患者按照研究要求,接受紫杉醇联合卡铂化疗治疗,两组患者分别接受不同的治疗,评估患者的临床效果,对比两组患者的观察指标,如:T细胞亚群、临床疗效。结果治疗后,CD8、CD4、CD3、CD4/CD8,研究组高于对照组;研究组中,CR+PR+SD人数多于对照组患者,且治疗总有效率高于对照组患者(P<0.05)。结论紫杉醇联合卡铂化疗治疗卵巢癌,能够提升患者自身的免疫功能,促进疾病的好转。

Objective To investigate the effect of paclitaxel combined with carboplatin on ovarian cancer. Methods From May 2018 to May 2019, 132 patients who met the inclusion and exclusion criteria, the investigators then divided the patients into a control group and a study group. The groups should be in accordance with scientific, reasonable, and random criteria. There were 67 patients in each group. The patients in the control group received carboplatin chemotherapy according to the research requirements. The patients in the study group received paclitaxel plus carboplatin chemotherapy according to the research requirements. The two groups received different treatments to evaluate the clinical effects of the patients. The observation indexes of the two groups of patients were compared, such as T cell subsets and clinical efficacy. Results After treatment, CD8, CD4, CD3, CD4/CD8, the study group was higher than the control group;in the study group, the number of CR+PR+SD was higher than that of the control group, and the total effective rate was higher than that of the control group(P<0.05). Conclusion Paclitaxel combined with carboplatin chemotherapy for ovarian cancer can improve the patient’s own immune function and promote the improvement of the disease.